Chinese PLA General Hospital is conducting an early phase I trial (NCT01864902) and will assess the safety and feasibility of CD33-engineered lymphocyte therapy in patients with AML that is relapsed or not responding to chemotherapy. This evidence concerns the gene CD33 and acute myeloid leukemia.